Skip to main content

Medicines Value Stock - Dividend - Research Selection


ISIN: US5846881051, WKN: 938858

Market price date: 30.11.-0001
Market price: 0,00 USD

Medicines Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-03-2019
Cash flow
Net operating cash flow -261.795.000
Capital Expenditures -7.000
Free cash flow -261.802.000
Balance sheet
Total Equity -22.000.000
Liabilities & Shareholders equity 841.686.000
Income statement
Net income -123.156.000
Eps (diluted) -1,680
Diluted shares outstanding 73.307.100
Net sales/revenue 6.138.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization6.223.772.672,00 USD
Raw Data Source
Stock Split

Description of the company

The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,